BioAtla has presented first-in-human Phase I study data of its anti-cancer therapy, BA3182, targeting those with ...

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

Nuravax, Institute for Molecular Medicine to present phase 1 results & phase 2 design of Alzheimer’s vaccine AV-1959R at CTAD 2025: Irvine, California Friday, July 4, 2025, 17:0 ...

Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of autoimmune diseases to the Center ...

Panelists discuss the SERENA-6 trial evaluating camizestrant, which uniquely enrolled patients with molecularly detected ESR1 ...

Fifty-five percent of the studies demonstrated alternative endpoint ... The researchers suggest that late-phase clinical trial design should focus on OS and QoL improvements to obtain the most valid ...

Obesity remains one of the greatest health challenges worldwide, leading to diabetes, heart disease, and increased healthcare ...